Literature DB >> 2918207

Intraventricular interferon treatment for subacute sclerosing panencephalitis.

I Steiner1, I Wirguin, A Morag, O Abramsky.   

Abstract

Three children with subacute sclerosing panencephalitis (SSPE) were treated with alpha-interferon. Medication was administered via an Ommaya reservoir into the cerebral ventricular system over a period of 13 to 24 months in increasing amounts up to 1.0 x 10(6) IU twice weekly. Mild clinical improvement in two children and a stable course in the third were associated with improvement of electroencephalographic recordings in all patients and a decrease in antimeasles antibodies in the cerebrospinal fluid of two. The small number of patients does not enable us to determine whether this course was the natural history of SSPE in our patients or whether it was induced by treatment, yet it seems that intraventricular interferon treatment can modify the course of SSPE.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2918207     DOI: 10.1177/088307388900400103

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  3 in total

1.  Toxic effect of intraventricular interferon-alpha in subacute sclerosing panencephalitis.

Authors:  C Cianchetti; A L Fratta; F Muntoni; G Marrosu; M G Marrosu
Journal:  Ital J Neurol Sci       Date:  1994-04

2.  A Novel Peptide Derived from the Fusion Protein Heptad Repeat Inhibits Replication of Subacute Sclerosing Panencephalitis Virus In Vitro and In Vivo.

Authors:  Masahiro Watanabe; Koichi Hashimoto; Yusaku Abe; Eiichi N Kodama; Ryota Nabika; Shinya Oishi; Shinichiro Ohara; Masatoki Sato; Yukihiko Kawasaki; Nobutaka Fujii; Mitsuaki Hosoya
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

Review 3.  CSF in acute and chronic infectious diseases.

Authors:  Felix Benninger; Israel Steiner
Journal:  Handb Clin Neurol       Date:  2017
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.